[go: up one dir, main page]

MX2011008413A - Tratamientos mejorados para migraña basados en mimeticos de grelina. - Google Patents

Tratamientos mejorados para migraña basados en mimeticos de grelina.

Info

Publication number
MX2011008413A
MX2011008413A MX2011008413A MX2011008413A MX2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A MX 2011008413 A MX2011008413 A MX 2011008413A
Authority
MX
Mexico
Prior art keywords
enhanced
treatments based
migraine
migraine treatments
ghrelin mimetics
Prior art date
Application number
MX2011008413A
Other languages
English (en)
Inventor
William J Polvino
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of MX2011008413A publication Critical patent/MX2011008413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a un método para mejorar la absorción de medicaciones para migraña y de esta manera tratar migrañas al co-administrar a un sujeto en necesidad del mismo una cantidad efectiva de un mimético de grelina o sal, hidrato o solvato farmacéuticamente aceptable del mismo y por lo menos una medicación para migraña seleccionada de un agonista de receptor de serotonina 5-HT1B/1D, un derivado de triptamina, un derivado de ergolina, un fármaco antiinflamatorio no esteroidal o un analgésico, o cualquier combinación de los mismos.
MX2011008413A 2009-02-27 2010-03-01 Tratamientos mejorados para migraña basados en mimeticos de grelina. MX2011008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15612909P 2009-02-27 2009-02-27
PCT/US2010/025725 WO2010099522A1 (en) 2009-02-27 2010-03-01 Enhanced migraine treatments based on ghrelin mimetics

Publications (1)

Publication Number Publication Date
MX2011008413A true MX2011008413A (es) 2011-09-22

Family

ID=42144981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008413A MX2011008413A (es) 2009-02-27 2010-03-01 Tratamientos mejorados para migraña basados en mimeticos de grelina.

Country Status (17)

Country Link
US (2) US8486976B2 (es)
EP (1) EP2400986B1 (es)
JP (1) JP6041491B2 (es)
KR (2) KR101707666B1 (es)
CN (1) CN102333545B (es)
AU (1) AU2010217792B2 (es)
BR (1) BRPI1008698A2 (es)
CA (1) CA2752813C (es)
EA (1) EA021055B1 (es)
ES (1) ES2558701T3 (es)
IL (1) IL214443A0 (es)
MX (1) MX2011008413A (es)
NO (1) NO20111303A1 (es)
SG (1) SG174158A1 (es)
TW (1) TWI457331B (es)
UA (1) UA105657C2 (es)
WO (1) WO2010099522A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
KR20120030530A (ko) * 2009-06-12 2012-03-28 헬신 세라퓨틱스 (유.에스.) 인크. 이파모렐린 디아세테이트 주사 및 주입 용액
CA2859173A1 (en) * 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN116999563A (zh) * 2017-05-10 2023-11-07 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2020237322A1 (en) * 2019-05-31 2020-12-03 Lateral IP Pty Ltd Peptides and uses thereof
BR112022002767A2 (pt) * 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426206T2 (de) * 1993-12-23 2001-05-17 Novo Nordisk A/S, Bagsvaerd Verbindungen mit wachstumshormonfreisetzenden eigenschaften
PL327227A1 (en) * 1995-12-22 1998-12-07 Novo Nordisk As Compounds exhibiting growth hormone liberating properties
ATE304528T1 (de) * 1996-07-22 2005-09-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
AU2405401A (en) * 1999-12-28 2001-07-09 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
US20100016363A1 (en) 2006-04-25 2010-01-21 Kowa Pharmaceuticals America, Inc. Fixed Combination Dosage Forms for the Treatment of Migraine
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法

Also Published As

Publication number Publication date
KR20110126155A (ko) 2011-11-22
SG174158A1 (en) 2011-10-28
US20100222388A1 (en) 2010-09-02
US8673947B2 (en) 2014-03-18
ES2558701T3 (es) 2016-02-08
CA2752813C (en) 2017-03-28
CN102333545A (zh) 2012-01-25
NO20111303A1 (no) 2011-09-26
US20130289068A1 (en) 2013-10-31
AU2010217792A1 (en) 2011-08-25
BRPI1008698A2 (pt) 2016-03-08
KR101707666B1 (ko) 2017-02-16
JP6041491B2 (ja) 2016-12-07
KR20160136473A (ko) 2016-11-29
UA105657C2 (uk) 2014-06-10
EA201171091A1 (ru) 2012-04-30
WO2010099522A1 (en) 2010-09-02
EP2400986B1 (en) 2015-10-14
TWI457331B (zh) 2014-10-21
AU2010217792B2 (en) 2015-10-22
TW201035071A (en) 2010-10-01
EA021055B1 (ru) 2015-03-31
CN102333545B (zh) 2014-03-19
EP2400986A1 (en) 2012-01-04
IL214443A0 (en) 2011-09-27
CA2752813A1 (en) 2010-09-02
US8486976B2 (en) 2013-07-16
JP2012519184A (ja) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2011008413A (es) Tratamientos mejorados para migraña basados en mimeticos de grelina.
Xu et al. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders
WO2011162989A3 (en) Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
WO2006055854A3 (en) Methods for reducing the side effects associated with mirtazapine treatment
PH12017500930A1 (en) Hsp90 inhibitor combinations
BR112017003570A2 (pt) tratamento de combinação de inibidores de sglt2 e agonistas de dopamina para prevenir distúrbios metabólicos em animais equinos
GB2468073A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
MX388258B (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2009003845A (es) Composiciones para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco.
MX2011006790A (es) Composiciones para administracion de farmacos.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2009129432A3 (en) Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
WO2011156479A3 (en) Trkb agonists and methods of use
MX2011008280A (es) Derivados de cilopropilamida hacia receptor de histamina h3.
BR112017000556A2 (pt) terapia de combinação para câncer
WO2009155139A9 (en) Use of isoindoles for the treatment of neurobehavioral disorders
BRPI0921097A2 (pt) composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento.
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
MX2009012427A (es) Derivados de la espirociclopropil piperidina.
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
MX385316B (es) Compuestos de morfinano.
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
MX351180B (es) Composicion farmaceutica que comprende derivados de piridona.

Legal Events

Date Code Title Description
FG Grant or registration